Sangamo Therapeutics Faces Delisting Notice

TL;DR

SGMO got a delisting notice, might be in trouble.

AI Summary

Sangamo Therapeutics, Inc. filed an 8-K on October 29, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company, formerly known as Sangamo Biosciences Inc., is incorporated in Delaware and headquartered in Richmond, California.

Why It Matters

This filing indicates potential issues with Sangamo Therapeutics' continued listing on an exchange, which could impact its stock trading and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock trading and overall financial stability.

Key Numbers

• 000-30171 — SEC File Number (Identifies the company's filings with the SEC.)

Key Players & Entities

• SANGAMO THERAPEUTICS, INC. (company) — Registrant
• SANGAMO BIOSCIENCES INC (company) — Former Company Name
• October 29, 2025 (date) — Date of Report
• 501 Canal Blvd., Richmond, California 94804 (address) — Principal Executive Offices
• 000-30171 (filing_id) — SEC File Number

FAQ

Key Financial Figures

• $0.01 — ange on which registered Common Stock, $0.01 par value per share SGMO Nasdaq Capital
• $1.00 — ment to maintain a minimum bid price of $1.00 per share for continued listing on The

Filing Documents

• sgmo-20251029.htm (8-K) — 32KB
• 0001001233-25-000015.txt ( ) — 146KB
• sgmo-20251029.xsd (EX-101.SCH) — 2KB
• sgmo-20251029_lab.xml (EX-101.LAB) — 21KB
• sgmo-20251029_pre.xml (EX-101.PRE) — 12KB
• sgmo-20251029_htm.xml (XML) — 3KB

01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On October 29, 2025, Sangamo Therapeutics, Inc. (the "Company") received a letter (the "Extension Notice") from The Nasdaq Stock Market LLC ("Nasdaq") advising that the Company has been granted a 180-day extension, or until April 27, 2026, to regain compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"), in accordance with Nasdaq Listing Rule 5810(c)(3)(A). If at any time prior to April 27, 2026, the bid price of the Company's common stock, par value $0.01 per share ("Common Stock"), closes at $1.00 per share or more for a minimum of 10 consecutive trading days, the Company will regain compliance with the Minimum Bid Price Requirement. The Extension Notice has no immediate effect on the listing of the Common Stock on The Nasdaq Capital Market and does not affect the Company's reporting requirements with the Securities and Exchange Commission ("SEC"). As previously disclosed on the Current Report on Form 8-K filed with the SEC on May 5, 2025, the Company received a letter on April 30, 2025 from the Listing Qualifications Staff of Nasdaq indicating that, based upon the closing bid price of the Common Stock, for the preceding 30 consecutive business days, the Company was not in compliance with the Minimum Bid Price Requirement. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided 180 days, or until October 27, 2025, to regain compliance with the Minimum Bid Price Requirement. The Company intends to cure the Minimum Bid Price Requirement by April 27, 2026, however if the Company does not regain compliance with the Minimum Bid Price Requirement during this period, the Company expects that Nasdaq will provide written notification to the Company that its Common Stock will

Forward-Looking Statements

Forward-Looking Statements Certain statements in this Current Report on Form 8-K (the "Current Report") are "forward-looking statements" that are subject to substantial risks and uncertainties. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this Current Report may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words and include, without limitation, statements regarding the Company's intent to regain compliance with the Minimum Bid Price Requirement, the potential to appeal a delisting determination by Nasdaq, and the Company's ability to continue its listing on Nasdaq. Forward-looking statements are based on the Company's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the Company's ability to regain compliance with, or thereafter continue to comply with, the Nasdaq listing requirements, including the Minimum Bid Price Requirement, the outcome of any Nasdaq hearing process and the Company's ability to continue its listing on Nasdaq; and the other important factors outlined under the caption "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC"), the most recent Form 10-Q filed with the SEC, as such factors may be updated from time to time in its other filings with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to up

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SANGAMO THERAPEUTICS, INC. Dated: October 29, 2025 By: /s/ SCOTT B. WILLOUGHBY Name: Scott B. Willoughby Title: Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR